Phage Biotechnology Corp.

Patents

Phage Biotechnology Corporation has aggressively protected their proprietary manufacturing process by multiple patent filings. The company has utilized the intellectual property law firm, of Knobbe, Martens, Olson & Bear L.L.P., headquartered in Newport Beach, California. Knobbe, Martens, Olson, & Bear L.L.P., is a highly regarded intellectual property firm, with over 90 lawyers who practice only intellectual property work.

Below is a list of US and international patent applications that have been filed by Phage, some of which are issued patents.

1. US Patent No. 6,268,178 (issued July 31, 2001): "Phage-Dependent Super-Production of Biologically Active Protein and Peptides." Recombinant host cells used in first generation Phage technology.

2. US Application No. 09/859,651 (filed May 17, 2001 – divisional of the ‘178 patent (#1); claims allowed by U.S. Patent Office, April 2004): "Phage-Dependent Super Production of Biologically Active Protein and Peptides." First generation Phage methods for producing recombinant proteins and peptides.

3. US Patent No. 6,773,899 (filed August 15, 2000, issued August 10, 2004): "Phage-Dependent Super Production of Biologically Active Protein and Peptides." Second generation Phage technology.

4. PCTUS00/40020 (filed May 24, 2000, published November 30, 2000, National phase November 16, 2001): "Phage-Dependent Super Production of Biologically Active Protein and Peptides." This is the international application for first generation Phage technology. Other national applications are pending in Europe and Japan.

5. PCTUS01/25477 (filed August 15, 2001, published February 21, 2002, National phase February 10, 2003): "Phage-Dependent Super Production of Biologically Active Protein and Peptides." This is the international application for second generation Phage technology. National applications are pending in Australia, Canada, Europe, Japan and Korea.

6. US Patent No. 6,642,026 (filed August 15, 2000, issued November 4, 2003): "Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and Its Use in Promoting Angiogenesis." Methods of producing Cardio Vascu-Grow™.

7. US Application No. 10/649,480 (filed August 27, 2003 – continuation-in-part application of both the ‘780 application (#1) and the ‘026 patent (#2)), "Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and Its Use in Promoting Angiogenesis." Methods of revascularizing ischemic tissues using Cardio Vascu-Grow™.

8. PCTUS01/25537 (filed August 15, 2001, published February 21, 2002, national phase February 10, 2003): "A Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and Its Use in Promoting Angiogenesis." International application for methods of manufacturing and using Cardio Vascu-Grow™. National applications pending in Australia, Canada, Japan, Korea and Europe. Europe includes the following 19 countries: Austria, Belgium, Switzerland, Liechtenstein, Cyprus, Germany, Denmark, Spain, Finland, France, United Kingdom, Greece, Ireland, Italy, Luxembourg, Monaco, Portugal, Netherlands, and Sweden.

Top